BridgeBio Pharma, Inc. last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $353.2 million (+192.6% year over year) and diluted EPS of -$0.42. It usually reports 12–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
353
+192.6%
|
-57
|
-0.42
+55.8%
|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
244
+120.4%
|
—
|
-0.78
+17.9%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
195
+66.8%
|
—
|
-0.84
+4.5%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
154
+2521.2%
|
—
|
-1.00
+28.8%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
121
+4318.0%
|
—
|
-0.95
-10.5%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
111
+4999.9%
|
—
|
-0.95
-143.6%
|
|
Apr 29, 2025
29 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
117
-44.8%
|
—
|
-0.88
-340.0%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
6
+237.1%
|
—
|
-1.40
-45.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1743881
- Former names
- BridgeBio Pharma LLC (until May 16, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.